Business Standard

Monday, December 23, 2024 | 12:12 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Serum likely to submit final Covid-19 vaccine trial data in 10 days

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca's vaccine candidate, can come in by the first week of January

Coronavirus, vaccine, covid, drugs, clinical trials
Premium

Sources said the Indian drug regulator is in touch with its counterpart in the UK, which is reviewing AstraZeneca's application

Sohini Das Mumbai
Serum Institute of India, that has completed phase-3 trial with over 1,600 volunteers in India, is expected to submit the final set of data before the subject expert committee in the next 10 days or so, according to people in the know.

If the data is found satisfactory, an approval for Covishield, Oxford-AstraZeneca’s vaccine candidate, can come in by the first week of January.

Last week, the panel, advising the country’s drug regulator on Covid-19 vaccines, sought additional data from Serum. The firm has completed phase-3 trial in India on November 25. The immunogenicity (whether the vaccine produces the desired immune response)

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in